IDEAYA Biosciences is a precision oncology company developing cancer therapies guided by molecular targets and biomarker-defined patient groups. Its pipeline centers on synthetic lethality and related mechanisms that exploit genetic dependencies in tumors. The business model is research- and development-driven, aimed at oncology indications where companion diagnostics can identify likely responders.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -77.5 | — |
| Q3 2025 | 207.8 | — | 119.2 | — |
| Q4 2025 | 10.9 | — | -83.3 | — |
| Q1 2026 | 6.6 | — | -98.5 | — |
| Q2 2026 | 8.9 | — | -112.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Grand Canyon Education, Inc. (LOPE), Tango Therapeutics, Inc. (TNGX), Independent Bank Corp. (INDB), WesBanco, Inc. (WSBC), Braze, Inc. (BRZE), Viking Therapeutics, Inc. (VKTX)